Bosch J
University of Barcelona School of Medicine, Spain.
P R Health Sci J. 2000 Mar;19(1):57-67.
The medical treatment of portal hypertension has experienced a marked progress in the past decade due to the introduction of effective portal hypotensive therapy. This has been possible because of the better understanding of the pathophysiological mechanisms leading to portal hypertension. A major step forward was the introduction of beta-blockers for the prevention of bleeding and rebleeding from gastroesophageal varices. Effective therapy requires the reduction of the hepatic venous pressure gradient (HVPG) to 12 mmHg or below, or at least by 20% of baseline values. Unfortunately, this is only achieved in 1/3 to 1/2 of patients. Combination therapy, associating isosorbide-5-mononitrate and propranolol or nadolol administration enhances the reduction in portal pressure and increases the number of patients in whom HVPG decreases by more than 20% of baseline values and below 12 mmHg. Randomized clinical trials (RCT's) do support the concept that combination therapy is more effective than propranolol or nadolol alone, significantly better than sclerotherapy, and probably than endoscopic banding ligation. Therapy may be complemented by the association of spironolactone. The main inconvenience of pharmacological therapy is that there is no non-invasive method available to detect non-responders to treatment. Failures of drug therapy should be managed endoscopically. Failures of endoscopic treatment require 'rescue' by means of TIPS or shunt surgery. Patients with advanced liver failure should be considered for orthotopic liver transplantation, and put into a waiting list if eligible. In the treatment of acute variceal bleeding pharmacological therapy offer the unique advantage of allowing to provide specific therapy immediately after arrival to hospital, or even during transferral to hospital by ambulance, since it does not require sophisticated equipment and highly qualified medical staff. Vasopressin has been abandoned because of its toxicity, although this can be reduced by the combined administration of transdermal nitroglycerin. Terlipressin has longer effects and is more effective and safer than vasopressin alone or in combination with nitroglycerin. It has proved to be effective and to decrease mortality from bleeding in double-blind studies. RCT's have shown that this drug is as effective and safer than emergency sclerotherapy. Therapy should be maintained for five days to prevent early rebleeding. Somatostatin is probably as effective as terlipressin. Octreotide is probably useful after endoscopic therapy but can not be recommended as first line treatment. Endoscopic injection sclerotherapy and endoscopic banding ligation are very effective, but require well trained medical staff. There is an increasing trend for initiating therapy with a pharmacological agent, followed by semi-emergency endoscopic therapy as soon as a well trained endoscopist is available (within 12-24 hours), while maintaining drug therapy for 5 days. Failures of medical therapy may be treated by a second session of endoscopic treatment, but if this fails TIPS of emergency surgery should be done. In high-risk situations, such as bleeding from gastric varices or in patients with advanced liver failure, the decision for TIPS or surgery should be done earlier, after failure of the initial treatment.
由于有效门脉降压疗法的引入,门脉高压的医学治疗在过去十年取得了显著进展。这之所以成为可能,是因为对导致门脉高压的病理生理机制有了更深入的了解。向前迈出的重要一步是引入β受体阻滞剂以预防胃食管静脉曲张出血和再出血。有效的治疗需要将肝静脉压力梯度(HVPG)降至12 mmHg或更低,或至少降低至基线值的20%以下。不幸的是,只有三分之一至二分之一的患者能达到这一目标。联合使用5-单硝酸异山梨酯与普萘洛尔或纳多洛尔进行联合治疗可增强门脉压力的降低,并增加HVPG降低超过基线值20%且低于12 mmHg的患者数量。随机临床试验(RCT)确实支持联合治疗比单独使用普萘洛尔或纳多洛尔更有效的观点,明显优于硬化疗法,可能也优于内镜下套扎术。螺内酯联合使用可补充治疗。药物治疗的主要不便之处在于没有非侵入性方法可检测对治疗无反应者。药物治疗失败应通过内镜处理。内镜治疗失败需要通过经颈静脉肝内门体分流术(TIPS)或分流手术进行“挽救”。晚期肝衰竭患者应考虑进行原位肝移植,符合条件者应列入等待名单。在急性静脉曲张出血的治疗中,药物治疗具有独特优势,即患者入院后甚至在通过救护车转运至医院的过程中即可立即进行特异性治疗,因为它不需要复杂设备和高素质医务人员。由于其毒性,加压素已被弃用,尽管联合经皮给予硝酸甘油可降低其毒性。特利加压素作用时间更长,比单独使用加压素或与硝酸甘油联合使用更有效且更安全。双盲研究已证明其有效且可降低出血死亡率。RCT表明该药物与急诊硬化疗法同样有效且更安全。治疗应持续五天以预防早期再出血。生长抑素可能与特利加压素效果相当。奥曲肽在内镜治疗后可能有用,但不推荐作为一线治疗。内镜注射硬化疗法和内镜下套扎术非常有效,但需要训练有素的医务人员。越来越多的趋势是先用药物治疗,一旦有训练有素的内镜医师(在12 - 24小时内),随即进行半急诊内镜治疗,同时药物治疗维持5天。药物治疗失败可通过再次内镜治疗处理,但如果再次失败则应进行TIPS或急诊手术。在高危情况下,如胃静脉曲张出血或晚期肝衰竭患者,在初始治疗失败后应更早决定是否进行TIPS或手术。